(Q33393623)

26 July 2017

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (English)

1 reference

26 July 2017

phase II clinical trial

0 references

C Haioun

8

0 references

author name string

T E Witzig

1

1 reference

26 July 2017

J M Vose

2

1 reference

26 July 2017

P L Zinzani

3

1 reference

26 July 2017

C B Reeder

4

1 reference

26 July 2017

R Buckstein

5

1 reference

26 July 2017

J A Polikoff

6

1 reference

26 July 2017

R Bouabdallah

7

1 reference

26 July 2017

H Tilly

9

1 reference

26 July 2017

P Guo

10

1 reference

26 July 2017

D Pietronigro

11

1 reference

26 July 2017

A L Ervin-Haynes

12

1 reference

26 July 2017

M S Czuczman

13

1 reference

26 July 2017

12 January 2011

1 reference

26 July 2017

1 reference

26 July 2017

22

1 reference

26 July 2017

1622-1627

1 reference

26 July 2017

7

1 reference

26 July 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ626

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ626

1 reference

26 July 2017

1 reference